| 1995 |
- |
Business formation |
| 1996 |
- |
IPO on Alternative Investment Market (London) |
| 1999 |
- |
First products commence clinical trials (renzapride and COLAL-PRED®) |
| 2000 |
- |
Listing on the Official List of the London Stock Exchange |
| 2003 |
- |
Successful results of Phase IIb clinical trial of cetilistat for obesity |
| |
- |
License and development option agreement with Takeda for cetilistat in Japan |
| |
- |
Successful results of Phase IIb clinical trial of renzapride for c-IBS |
| |
- |
Successful results of Phase IIb clinical trial of renzapride for m-IBS |
| 2004 |
- |
Takeda exercise option to take up rights to cetilistat for Japan |
| 2005 |
- |
Successful results of Phase IIb clinical trial of cetilistat for obese diabetics |
| |
- |
Agreement with FDA through Special Protocol Assessment for Phase III clinical trial in the US of renzapride for IBS |
| |
- |
Approval from the MHRA to conduct Phase III registration clinical trial in EU of COLAL-PRED® for ulcerative colitis |
| 2006
|
- |
Takeda commence Phase II clinical trial of cetilistat |
| |
- |
Progression of patient recruitment into US Phase III clinical trial of renzapride |
| |
- |
Progression of patient recruitment into EU Phase III clinical trial of COLAL-PRED® for ulcerative colitis |
| |
- |
Successful results of Phase IIa ‘proof of concept’ clinical trial of ATL-104 for mucositis |
| 2007
|
- |
Licence agreement with Prometheus Laboratories Inc for COLAL-PRED® in North America |
| |
- |
Co-development agreement with TSD Japan Inc for COLAL-PRED® in Japan |
| 2008
|
- |
FDA agreement under SPA of all three protocols for Phase III study of cetilistat in obesity |
| |
- |
Licence agreement with Norgine BV for COLAL-PRED® in the EU and other territories |
| |
- |
Takeda commence Phase III clinical trial of cetilistat in Japan |
